Evidence map›Paper›PMID 36805385›Full record

ArticleInternational journal of clinical oncology2023

Correction to: Repeated SARS-CoV-2 vaccination in cancer patients treated with immune checkpoint inhibitors: induction of high-avidity anti-RBD neutralizing antibodies.

Teresita Caruso, Francesca Salani, Silvia Catanese, Federico Pratesi, Chiara Mercinelli, Giuseppe Motta, Virginia Genovesi, Adele Bonato, Galimberti Sara, Gianluca Masi and 1 more

Open access · hybridAbstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Teresita Caruso *Clinical Immunology and Allergy Unit, Department of Clinical and Experimental Medicine, University of Pisa, Via Roma, 67, 56126, Pisa, Italy.
Francesca Salani *Oncology Unit, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy.
Silvia CataneseDepartment of Translational Medicine and New Technologies for Medicine and Surgery, University of Pisa, Pisa, Italy.
Federico PratesiClinical Immunology and Allergy Unit, Department of Clinical and Experimental Medicine, University of Pisa, Via Roma, 67, 56126, Pisa, Italy.ORCID http://orcid.org/0000-0002-7226-0907
Chiara MercinelliOncology Unit, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy.
Giuseppe MottaClinical Immunology and Allergy Unit, Department of Clinical and Experimental Medicine, University of Pisa, Via Roma, 67, 56126, Pisa, Italy.
Virginia GenovesiOncology Unit, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy.
Adele BonatoOncology Unit, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy.
Galimberti SaraHematology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Gianluca MasiDepartment of Translational Medicine and New Technologies for Medicine and Surgery, University of Pisa, Pisa, Italy.
Paola MiglioriniClinical Immunology and Allergy Unit, Department of Clinical and Experimental Medicine, University of Pisa, Via Roma, 67, 56126, Pisa, Italy. paola.migliorini@unipi.it.
University of Pisa · ITAzienda Ospedaliera Universitaria Pisana · ITScuola Superiore Sant'Anna · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID36805385
PMCPMC9939851
OpenAlexW4321478364

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.